Stock Events

Sosei 

¥1,550
3
+¥94+6.46% Today

Statistics

Day High
1,561
Day Low
1,450
52W High
3,185
52W Low
1,296
Volume
2,935,800
Avg. Volume
1,215,858
Mkt Cap
148.61B
P/E Ratio
1,374.24
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

10NovConfirmed
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-25.39
-7.52
10.34
28.21
Expected EPS
N/A
Actual EPS
3.82

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4565.TSE. It's not an investment recommendation.

About

Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of HTL0022562, a calcitonin gene related peptide antagonist, which is in Phase I clinical study; HTL0016878 for neurological diseases; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; and TMP301 and BHV3100 for neurological disorders, which is in clinical trials. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.
Show more...
CEO
Mr. Shinichi Tamura
Employees
205
Country
JP
ISIN
JP3431300007
WKN
000A0B7EK

Listings